Director Shareholding

Phytopharm PLC
7 May 2003


                       DEALINGS BY DIRECTORS


1)  NAME OF COMPANY
PHYTOPHARM PLC


2)  NAME OF DIRECTOR
DR R P DIXEY


3)  Please state whether notification indicates that it is in respect of
    holding of the shareholder named in 2 above or in respect of a
    non-beneficial interest or in the case of an individual holder
    if it is a holding of that person's spouse or children under the
    age of 18 or in respect of an non-beneficial interest
AS 2 ABOVE


4)  Name of the registered holder(s) and, if more than one holder, the
    number of shares held by each of them. (If notified)
AS 2 ABOVE


5)  Please state whether notification relates to a person(s) connected
    with the Director named in 2 above and identify the connected person(s)
AS 2 ABOVE


6)  Please state the nature of the transaction. For PEP transactions
    please indicate whether general/single co PEP and if discretionary/non
    discretionary
GRANT OF SHARE OPTIONS UNDER THE PHYTOPHARM SHARE OPTION PLAN 2003


7)  Number of shares/amount of
    stock acquired



8)   ( %)
    of issued Class



9)  Number of shares/amount
    of stock disposed



10)  ( %)
    of issued Class



11) Class of security



12) Price per share



13) Date of transaction



14) Date company informed



15) Total holding following this notification



16) Total percentage holding of issued class following this notification



     IF A DIRECTOR HAS BEEN GRANTED OPTIONS BY THE COMPANY PLEASE
                    COMPLETE THE FOLLOWING BOXES

17) Date of grant
2 MAY 2003


18) Period during which or date on which exercisable
FROM 3 MAY 2006 TO 2 MAY 2013 SUBJECT TO PERFORMANCE CRITERIA


19) Total amount paid (if any) for grant of the option
NIL


20) Description of shares or debentures involved: class, number.
48,649 PHYTOPHARM PLC ORDINARY 1 PENCE SHARES


21) Exercise price (if fixed at time of grant) or indication that price
    is to be fixed at time of exercise
142.5 PENCE


22) Total number of shares or debentures over which options held
    following this notification
544,260 ORDINARY SHARES


23) Any additional information
PERFORMANCE CRITERIA ARE BASED ON TOTAL SHAREHOLDER RETURN COMPARED TO
COMPARATOR GROUPS AT THE THIRD, FOURTH AND FIFTH ANNIVERSARIES OF GRANT.  NO
OPTIONS VEST FOR BELOW MEDIAN PERFORMANCE, 25% VEST FOR MEDIAN PERFORMANCE AND
100% VEST FOR UPPER DECILE AND ABOVE WITH PRORATA VESTING BETWEEN MEDIAN AND
UPPER DECILE PERFORMANCE.  FOR 32,433 OPTIONS THE COMPARATOR GROUP COMPRISES 27
OTHER UK LISTED BIOTECH COMPANIES, AND FOR 16,216 OPTIONS THE COMPARATOR GROUP
IS THE FTSE SMALL CAP INDEX.


24) Name of contact and telephone number for queries
DR S C LOACH - 01480 437697


25) Name and signature of authorised company official responsible for
    making this notification

    Date of Notification       7 MAY 2003



                       DEALINGS BY DIRECTORS


1)  NAME OF COMPANY
PHYTOPHARM PLC


2)  NAME OF DIRECTOR
DR D D REES


3)  Please state whether notification indicates that it is in respect of
    holding of the shareholder named in 2 above or in respect of a
    non-beneficial interest or in the case of an individual holder
    if it is a holding of that person's spouse or children under the
    age of 18 or in respect of an non-beneficial interest
AS 2 ABOVE


4)  Name of the registered holder(s) and, if more than one holder, the
    number of shares held by each of them. (If notified)
AS 2 ABOVE


5)  Please state whether notification relates to a person(s) connected
    with the Director named in 2 above and identify the connected person(s)
AS 2 ABOVE


6)  Please state the nature of the transaction. For PEP transactions
    please indicate whether general/single co PEP and if discretionary/non
    discretionary
GRANT OF SHARE OPTIONS UNDER THE PHYTOPHARM SHARE OPTION PLAN 2003


7)  Number of shares/amount of
    stock acquired



8)   ( %)
    of issued Class



9)  Number of shares/amount
    of stock disposed



10)  ( %)
    of issued Class



11) Class of security



12) Price per share



13) Date of transaction



14) Date company informed



15) Total holding following this notification



16) Total percentage holding of issued class following this notification



     IF A DIRECTOR HAS BEEN GRANTED OPTIONS BY THE COMPANY PLEASE
                    COMPLETE THE FOLLOWING BOXES

17) Date of grant
2 MAY 2003


18) Period during which or date on which exercisable
FROM 3 MAY 2006 TO 2 MAY 2013 SUBJECT TO PERFORMANCE CRITERIA


19) Total amount paid (if any) for grant of the option
NIL


20) Description of shares or debentures involved: class, number.
33,342 PHYTOPHARM PLC ORDINARY 1 PENCE SHARES


21) Exercise price (if fixed at time of grant) or indication that price
    is to be fixed at time of exercise
142.5 PENCE


22) Total number of shares or debentures over which options held
    following this notification
559,014 ORDINARY SHARES


23) Any additional information
PERFORMANCE CRITERIA ARE BASED ON TOTAL SHAREHOLDER RETURN COMPARED TO
COMPARATOR GROUPS AT THE THIRD, FOURTH AND FIFTH ANNIVERSARIES OF GRANT.  NO
OPTIONS VEST FOR BELOW MEDIAN PERFORMANCE, 25% VEST FOR MEDIAN PERFORMANCE AND
100% VEST FOR UPPER DECILE AND ABOVE WITH PRORATA VESTING BETWEEN MEDIAN AND
UPPER DECILE PERFORMANCE.  FOR 22,228 OPTIONS THE COMPARATOR GROUP COMPRISED 27
OTHER UK LISTED BIOTECH COMPANIES, AND FOR 11,114 OPTIONS THE COMPARATOR GROUP
IS THE FTSE SMALL CAP INDEX.


24) Name of contact and telephone number for queries
DR S C LOACH - 01480 437697


25) Name and signature of authorised company official responsible for
    making this notification

    Date of Notification        7 MAY 2003



                      This information is provided by RNS
            The company news service from the London Stock Exchange